NCT02934932View on ClinicalTrials.gov

A Pilot Dose-Response Biomarker Study of Brexpiprazole Treatment in PTSD

PHASE2TerminatedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

April 25, 2017

Primary Completion Date

April 30, 2018

Study Completion Date

April 30, 2018

Conditions
Post Traumatic Stress Disorder
Interventions
DRUG

Brexpiprazole

Comparison of brexpiprazole 2mg to placebo Comparison of brexpiprazole 4mg to placebo

Trial Locations (1)

27712

Pamela Smith, Durham

Sponsors

Lead Sponsor

Duke University
All Listed Sponsors
collaborator

Otsuka America Pharmaceutical

INDUSTRY

lead

Duke University

OTHER